Nomura Holdings Inc. boosted its position in Allergan plc (NYSE:AGN) by 528.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 309,062 shares of the company’s stock after acquiring an additional 259,900 shares during the period. Nomura Holdings Inc.’s holdings in Allergan were worth $51,810,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Liberty Wealth Management LLC lifted its stake in Allergan by 35.3% in the second quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock valued at $43,000 after buying an additional 67 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in Allergan by 1.8% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 4,274 shares of the company’s stock valued at $626,000 after buying an additional 75 shares in the last quarter. Berman Capital Advisors LLC grew its holdings in Allergan by 48.8% during the 1st quarter. Berman Capital Advisors LLC now owns 238 shares of the company’s stock valued at $34,000 after buying an additional 78 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its holdings in Allergan by 43.1% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 259 shares of the company’s stock valued at $44,000 after buying an additional 78 shares in the last quarter. Finally, Bank of Hawaii grew its holdings in Allergan by 1.4% during the 1st quarter. Bank of Hawaii now owns 6,463 shares of the company’s stock valued at $946,000 after buying an additional 89 shares in the last quarter. 80.45% of the stock is owned by institutional investors.
Several research firms have weighed in on AGN. Cantor Fitzgerald raised their price target on Allergan from $125.00 to $165.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Wells Fargo & Co restated a “buy” rating and set a $176.00 price objective (down from $188.00) on shares of Allergan in a report on Wednesday, August 14th. Leerink Swann downgraded Allergan from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $217.00 to $188.00 in a report on Thursday, July 18th. ValuEngine downgraded Allergan from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Finally, Royal Bank of Canada restated a “hold” rating and set a $178.00 price objective on shares of Allergan in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $178.75.
Shares of NYSE:AGN traded up $0.92 on Friday, reaching $166.65. The company had a trading volume of 2,159,523 shares, compared to its average volume of 3,013,323. Allergan plc has a 52-week low of $114.27 and a 52-week high of $197.00. The firm’s 50 day simple moving average is $161.19 and its 200-day simple moving average is $149.43. The firm has a market capitalization of $54.36 billion, a PE ratio of 9.99, a PEG ratio of 2.16 and a beta of 1.61. The company has a current ratio of 1.03, a quick ratio of 0.91 and a debt-to-equity ratio of 0.34.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The business had revenue of $4.09 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same period last year, the business posted $4.42 EPS. The business’s revenue was down .8% compared to the same quarter last year. As a group, equities research analysts predict that Allergan plc will post 16.68 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Tuesday, August 13th were issued a $0.74 dividend. The ex-dividend date was Monday, August 12th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.78%. Allergan’s dividend payout ratio is presently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Further Reading: What is the market perform rating?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.